French venture studio M2care raises €26 million to accelerate the creation and development of innovative healthcare projects

M2care, a Lyon-based HealthTech venture studio, announces the completion of its €26 million fundraising with the participation of a new institutional investor, the French Tech Accélération 2 (FTA2) fund – managed by Bpifrance on behalf of the French government.

The amount was raised alongside existing investors Mérieux Développement, Institut NAOS des Sciences de la Vie, Crédit Agricole Centre-Est, and Family Offices. This new operation will finance the creation and development of eight innovative projects in the healthcare sector.

Florence Thueux, President of M2care, said: “I am delighted that France 2030’s French Tech Acceleration 2 fund has invested in our studio. Bpifrance is a leading player whose strong support will help to bring healthcare innovations to patients and into the market. I would like to sincerely thank Pierre Gillet, Océane Fleury, and the Bpifrance team for the trust they have placed in us.”

Founded in 2017, M2care is a venture studio created by Mérieux Développement and CEA Investissement, specialising in HealthTech. M2care founds, develops, and finances projects at early stages of maturity, alongside project leaders.

M2care acts as a link between academics, investors, and industry, thanks to its investment and operational deployment capabilities. With an experienced and complementary team of entrepreneurs in residence, an international network, and ad-hoc ecosystems built for each project, M2care aims to enable ideas and technologies born in laboratories to become health products brought to market, serving public health improvement and benefiting patients.

M2care has already invested in three projects, currently being co-developed alongside the Founders:

• Previa Medical, a company that has designed a digital medical device intended to predict and prevent medical emergencies in hospitals.

• TheraSonic, which is developing a medical device based on the use of ultrasound and intended to improve the treatment of brain diseases.

• Rhovica Neuroimaging, which is developing a ventricular drainage catheter with integrated sensors to optimise the treatment of emergency patients at risk of increased intracranial pressure – as reported by EU-Startups.

M2care is currently advancing projects primarily in cardiology, dermatology, ophthalmology, and neurology, and is preparing to launch a fourth project within the studio.

Carsten Laue, General Manager of M2care, added: “We are very pleased that France 2030’s FTA 2 fund, managed on behalf of the French government by Bpifrance, is supporting our venture studio and helping to create pioneering HealthTech startups.”

The French Tech Acceleration 2 fund has €100 million in funding. It was launched as part of the Investments for the Programme d’Investissements d’Avenir (PIA) and is now part of France 2030. Created as part of the French Tech public initiative, its aim is to use its investments to promote the development of startup acceleration structures (accelerators, startup studios, acceleration investment funds, etc.).

The French Tech Acceleration 2 fund is investing in M2care with the aim of promoting healthcare innovation and accelerating the transfer of technologies developed in academic laboratories to market, for the benefit of patients and public health. With this fundraising, M2care aims to create and develop eight new healthcare projects.

Pierre Gillet, Investment Director at Bpifrance, concluded: “By investing in M2care, we are reaffirming our commitment to strengthening our technological sovereignty in healthcare. We are delighted to contribute to this effort on behalf of the French government.”

The post French venture studio M2care raises €26 million to accelerate the creation and development of innovative healthcare projects appeared first on EU-Startups.